Cyprotex PLC ("Cyprotex" or the "Company")
Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces the appointment of Christopher Gurth Clothier as Non-Executive Director, effective as of 1st November 2010. Mr Clothier will serve on the Audit and Remuneration Committees of the Company.
Mr Clothier, aged 31, is currently Investment Director at IPGL Limited, the Company's second largest shareholder, with a holding of 27, 024,465 ordinary shares representing 12.08% of the issued share capital of the Company. Mr Clothier has previously been Investment Director at MMC Ventures, and a consultant with Roland Berger Strategy Consultants GmbH. Mr Clothier received his MChem from New College, University of Oxford, in 2002.
Mr Steve Harris, Non-Executive Chairman of Cyprotex, said: "We are delighted to welcome Chris Clothier to our Board as Non-Executive Director. Chris brings a wealth of knowledge of the Company and will have invaluable strategic input into the business going forward. The Company's three largest shareholders are now represented on the Board, whose interests are fully aligned with those of the rest of our shareholders."
Mr Chris Clothier added: "I am delighted to be joining Cyprotex at such an exciting time for the business. The recent acquisition of US-based Apredica has substantially enhanced the Company's presence in the US, and has accelerated its entry into the fast-growing in vitro toxicology market, both of which represent significant growth opportunities. As a representative of Cyprotex's second-largest shareholder, I am personally committed to helping the Company enhance shareholder value."
There is no further information to disclose in relation to Schedule 2 paragraph g of the AIM Rules for Companies.
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Singer Capital Markets Limited (broker to Cyprotex)
Tel: +44 (0) 20 3205 7500
Tel: +44 (0) 20 7831 3113